BRTX

BioRestorative Therapies, Inc. [BRTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BRTX Stock Summary

In the News

12:01 11 Dec 2023 BRTX

Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)

On July 25, 2023, Lance Alstodt, President, CEO, COB, and 10% Owner of BioRestorative Therapies Inc ( BRTX , Financial), made a significant purchase of 4200 shares of the company's stock. This move is noteworthy as insider buying can often be a positive indicator for the company's future performance.

07:00 11 Dec 2023 BRTX

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET 

10:02 11 Dec 2023 BRTX

5 Penny Stocks To Watch With Big News This Week

Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:29 11 Dec 2023 BRTX

BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event

Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit. During the presentation, BioRestorative Therapies Chief Executive Officer, Lance Alstdot, will highlight the Company's regenerative medicine platform and technology.

07:00 11 Dec 2023 BRTX

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be presenting at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022 at the Wyndham Grand Hotel in Jupiter, Florida.

03:52 11 Dec 2023 BRTX

4 Top Penny Stocks To Buy Right Now According To Insiders

Insiders decided to buy these penny stocks recently The post 4 Top Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:00 11 Dec 2023 BRTX

BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference

MELVILLE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that Lance Alstodt, its Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually from January 10-13, 2022.

09:55 11 Dec 2023 BRTX

Best Penny Stocks to Buy in January 2022? Check These 3 Out

Check these penny stocks out for your January 2022 watchlist The post Best Penny Stocks to Buy in January 2022? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:39 11 Dec 2023 BRTX

BioRestorative Therapies Stock (BRTX): Why The Price Surged Today

The stock price of BioRestorative Therapies Inc (NASDAQ: BRTX) increased by over 45% pre-market today. This is why it happened.

09:00 11 Dec 2023 BRTX

BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program

MELVILLE, N.Y., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“ BioRestorative ” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance for a patent application for its metabolic ThermoStem® program.

BRTX Financial details

Company Rating
Neutral
Market Cap
8.38M
Income
-12.49M
Revenue
130.2K
Book val./share
2.81
Cash/share
2.68
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
13 Nov 2023
P/E
-0.65
Forward P/E
-0.7
PEG
0.07
P/S
64.35
P/B
0.63
P/C
0.66
P/FCF
-1.28
Quick Ratio
13.17
Current Ratio
13.51
Debt / Equity
0.02
LT Debt / Equity
0
-
-
EPS (TTM)
-3.36
EPS next Y
-2.53
EPS next Q
-0.67
EPS this Y
-80.25%
EPS next Y
-24.66%
EPS next 5Y
-31.06%
EPS last 5Y
-74.1%
Revenue last 5Y
1.54%
Revenue Q/Q
-52.4%
EPS Q/Q
-97.64%
-
-
-
-
SMA20
-3.17%
SMA50
13.66%
SMA100
-43.17%
Inst Own
5.27%
Inst Trans
0.61%
ROA
-91%
ROE
-92%
ROC
-1.3%
Gross Margin
100%
Oper. Margin
-12813%
Profit Margin
-9596%
Payout
-
Shs Outstand
4.71M
Shs Float
3.73M
-
-
-
-
Target Price
-
52W Range
1.405-7.13
52W High
-74.57%
52W Low
+78%
RSI
44.92
Rel Volume
0.1
Avg Volume
32.82K
Volume
3.28K
Perf Week
-1.66%
Perf Month
-4.3%
Perf Quarter
-70.38%
Perf Half Y
-66.1%
-
-
-
-
Beta
58.218
-
-
Volatility
0.05%, 0.06%
Prev Close
-0.56%
Price
1.78
Change
3.07%

BRTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
37.866.680.110.040.03
Net income per share
-4.27K-920.83-17.13-25.21-4.98
Operating cash flow per share
-1.74K-355.5-2.75-2.8-1.62
Free cash flow per share
-1.75K-357.33-2.75-2.83-1.74
Cash per share
40.080.094.2817.74.08
Book value per share
-2.95K-656.47-1.8618.184.38
Tangible book value per share
-3.22K-694.45-2.7917.694.15
Share holders equity per share
-2.95K-656.47-1.8618.184.38
Interest debt per share
2.51K662.438.992.090.09
Market cap
10.56M389.24K19.75M5.15M9.95M
Enterprise value
14.59M8.14M21.48M-15.2M8.57M
P/E ratio
-0.84-0.02-1.61-0.17-0.55
Price to sales ratio
95.092.99256.48112.0683.05
POCF ratio
-2.07-0.06-10.05-1.55-1.69
PFCF ratio
-2.06-0.06-10.05-1.53-1.58
P/B Ratio
-1.22-0.03-14.830.240.63
PTB ratio
-1.22-0.03-14.830.240.63
EV to sales
131.4262.62278.92-330.4671.57
Enterprise value over EBITDA
-1.65-0.81-6.530.36-0.45
EV to operating cash flow
-2.86-1.18-10.934.57-1.46
EV to free cash flow
-2.85-1.17-10.934.52-1.36
Earnings yield
-1.19-46.04-0.62-5.81-1.81
Free cash flow yield
-0.48-17.87-0.1-0.65-0.63
Debt to equity
-0.48-0.61-3.60.030.02
Debt to assets
3.485.291.10.030.02
Net debt to EBITDA
-0.46-0.77-0.530.480.07
Current ratio
0.020.013.0559.0134.36
Interest coverage
-2.37-1.64-1.68-14.49-1.63K
Income quality
0.410.470.170.080.32
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
53.0950.1424.99556.79130.05
Research and developement to revenue
13.6313.2511.3915.8529.33
Intangibles to total assets
0.680.50.150.030.05
Capex to operating cash flow
00.0100.010.07
Capex to revenue
-0.12-0.270-0.67-3.67
Capex to depreciation
-0.05-0.160-0.34-3.65
Stock based compensation to revenue
21.6212.768.98502.37105.28
Graham number
16.83K3.69K26.78101.5522.14
ROIC
1.482.34-0.75-0.78-1.12
Return on tangible assets
-33.09-24.65-3.33-1.37-1.15
Graham Net
-3.31K-730.49-3.6416.993.91
Working capital
-9.07M-13.65M2.14M21.1M14.69M
Tangible asset value
-9.46M-13.52M-2M21.01M15.03M
Net current asset value
-9.65M-14.17M-2.49M20.61M14.53M
Invested capital
-0.48-0.61-3.60.030.02
Average receivables
33.5K30.5K24.5K11K10.5K
Average payables
2.17M1.92M1.04M84.84K110.86K
Average inventory
00000
Days sales outstanding
95.3689.8580.5839.6748.75
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
3.834.064.539.27.49
Payables turnover
00000
Inventory turnover
00000
ROE
1.451.49.2-1.39-1.14
Capex per share
-4.39-1.830-0.03-0.12

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.0100.010.020.01
Net income per share
-1.29-1.06-1.51-0.77-0.02
Operating cash flow per share
-0.4-0.43-0.63-0.29-0.26
Free cash flow per share
-0.39-0.5-0.65-0.3-0.26
Cash per share
4.534.083.332.992.68
Book value per share
4.674.383.633.192.81
Tangible book value per share
4.524.153.4232.65
Share holders equity per share
4.674.383.633.192.81
Interest debt per share
0.10.080.070.040.03
Market cap
11.76M9.95M12.64M17.14M8.18M
Enterprise value
5.52M8.57M11.07M15.59M5.94M
P/E ratio
-0.63-0.65-0.56-1.44-24.55
Price to sales ratio
405.672.69K403.81265.72266.51
POCF ratio
-8.1-6.32-5.38-15.16-6.95
PFCF ratio
-8.24-5.56-5.25-14.78-6.88
P/B Ratio
0.690.630.941.380.64
PTB ratio
0.690.630.941.380.64
EV to sales
190.482.32K353.72241.69193.6
Enterprise value over EBITDA
-1.2-1.79-1.93-5.07-1.91
EV to operating cash flow
-3.81-5.45-4.71-13.79-5.05
EV to free cash flow
-3.87-4.79-4.6-13.45-5
Earnings yield
-0.4-0.38-0.44-0.17-0.01
Free cash flow yield
-0.12-0.18-0.19-0.07-0.15
Debt to equity
0.020.020.020.020.02
Debt to assets
0.020.020.020.020.01
Net debt to EBITDA
1.360.290.270.50.72
Current ratio
23.5534.3627.1814.8213.51
Interest coverage
-159.83272.35317.2532.450.34
Income quality
0.310.360.410.380.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
125.851.08K137.3534.3173.63
Research and developement to revenue
34.11182.0648.2815.0128.5
Intangibles to total assets
0.030.050.060.060.05
Capex to operating cash flow
-0.020.140.030.030.01
Capex to revenue
0.85-58.81-1.92-0.45-0.39
Capex to depreciation
0.79-6.84-1.53-0.7-0.28
Stock based compensation to revenue
106.02826.56106.6823.0348.65
Graham number
11.6510.211.17.421.07
ROIC
-0.26-0.25-0.41-0.23-0.12
Return on tangible assets
-0.27-0.24-0.42-0.24-0.01
Graham Net
4.283.913.172.762.47
Working capital
16.17M14.69M12.31M11.23M11.67M
Tangible asset value
16.47M15.03M12.71M11.65M12.09M
Net current asset value
15.97M14.53M12.19M11.15M11.63M
Invested capital
0.020.020.020.020.02
Average receivables
30.5K30.5K16K20.5K32.15K
Average payables
423.37K319.7K131.74K184.32K251.7K
Average inventory
00000
Days sales outstanding
139.66389.1946.0134.88115.21
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.640.231.962.580.78
Payables turnover
00000
Inventory turnover
00000
ROE
-0.28-0.24-0.42-0.24-0.01
Capex per share
0.01-0.06-0.02-0.010

BRTX Frequently Asked Questions

What is BioRestorative Therapies, Inc. stock symbol ?

BioRestorative Therapies, Inc. is a US stock , located in Melville of Ny and trading under the symbol BRTX

What is BioRestorative Therapies, Inc. stock quote today ?

BioRestorative Therapies, Inc. stock price is $1.78 today.

Is BioRestorative Therapies, Inc. stock public?

Yes, BioRestorative Therapies, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap